Novagali Pharma SA – Product Pipeline Review – Q1 2011

Date: March 1, 2011
Pages: 47
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: NC5CA0FFBBBEN
Leaflet:

Download PDF Leaflet

Novagali Pharma SA – Product Pipeline Review – Q1 2011
Novagali Pharma SA - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Novagali Pharma SA - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Novagali Pharma SA - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Novagali Pharma SA human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Novagali Pharma SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Novagali Pharma SA’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Novagali Pharma SA’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Novagali Pharma SA in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Novagali Pharma SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Novagali Pharma SA.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Novagali Pharma SA and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Novagali Pharma SA Snapshot
Novagali Pharma SA Overview
Key Information
Key Facts
Novagali Pharma SA – Research and Development Overview
Key Therapeutic Areas
Novagali Pharma SA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Novagali Pharma SA – Pipeline Products Glance
Novagali Pharma SA – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Novagali Pharma SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Novagali Pharma SA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Novagali Pharma SA – Drug Profiles
Cyclokat
Product Description
Mechanism of Action
R&D Progress
Vekacia
Product Description
R&D Progress
Catioprost
Product Description
Mechanism of Action
R&D Progress
Nova-21048
Product Description
Mechanism of Action
R&D Progress
Cortiject
Product Description
Mechanism of Action
R&D Progress
Nova-21048
Product Description
Mechanism of Action
R&D Progress
Nova-22038
Product Description
Mechanism of Action
R&D Progress
Novagali Pharma SA – Pipeline Analysis
Novagali Pharma SA – Pipeline Products by Therapeutic Class
Novagali Pharma SA - Pipeline Products By Target
Novagali Pharma SA – Pipeline Products by Route of Administration
Novagali Pharma SA – Pipeline Products by Molecule Type
Novagali Pharma SA – Recent Pipeline Updates
Novagali Pharma SA - Dormant Projects
Novagali Pharma SA – Locations And Subsidiaries
Head Office
Recent Developments
May 06, 2009: Novagali Pharma Announces FDA Clearance Of IND For Phase III Of Catioprost In Patients With Glaucoma
Apr 15, 2009: Novagali Pharma Completes Phase II Clinical Trial With Cyclokat In Dry Eye
Feb 27, 2009: Novagali Pharma Presents Results Of Its Latanoprost Formulation Drug Catioprost For Glaucoma
Nov 18, 2008: Novagali Pharma Withdraws Marketing Authorization Application For Vekacia
Apr 23, 2008: Novagali Pharma Successfully Enrolls First Patient In U.S. Phase I Clinical Study With Cortiject For Diabetic Macular Edema
Jun 25, 2007: Novagali Pharma Presents Results Of Pivotal Phase III Clinical Trial With Vekacia At AACO
May 24, 2007: Novagali Pharma Receives US FDA Orphan Drug Designation For Vekacia For The Treatment Of Vernal Keratoconjunctivitis
Apr 26, 2007: Novagali Pharma Announces FDA Clearance Of IND For Phase III Trial Of Nova22007 For Treatment Of Dry Eye Syndrome
Apr 04, 2007: Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial In Vernal Keratoconjunctivitis
Jan 18, 2007: Novagali Pharma Announces FDA Clearance Of IND For US Clinical Trial Of Nova63035 In Patients With Diabetic Macular Edema
Financial Deals Landscape
Novagali Pharma SA, Deals Volume Summary, 2004 to YTD 2011
Novagali Pharma SA, Deals Summary By Region, 2004 to YTD 2011
Novagali Pharma SA, Deals Summary, 2004 to YTD 2011
Novagali Pharma SA Detailed Deal Summary
Asset Purchase
Spring Energy Acquires 20% Interest In PL 377S From Idemitsu Petroleum
Venture Financing
Novagali Pharma Secures $22 Million In Financing
Novagali Pharma Secures $32 Million In Series C Financing
Novagali Pharma Secures $11.21 Million In Second Close Of Series B Financing
Licensing Agreements
TOPIGEN Pharmaceuticals Enters Into Licensing Agreement With Novagali Pharma
TOPIGEN Pharmaceuticals Enters Into Licensing Agreement With Novagali Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Novagali Pharma SA – Pipeline by Therapy Area and Indication, 2011
Novagali Pharma SA – Pipeline by Stage of Development, 2011
Novagali Pharma SA – Monotherapy Products in Pipeline, 2011
Novagali Pharma SA – Phase III, 2011
Novagali Pharma SA - Phase II, 2011
Novagali Pharma SA - Phase I, 2011
Novagali Pharma SA - Pipeline By Therapeutic Class, 2011
Novagali Pharma SA - Pipeline By Target, 2011
Novagali Pharma SA – Pipeline By Route of Administration, 2011
Novagali Pharma SA – Pipeline By Molecule Type, 2011
Novagali Pharma SA – Recent Pipeline Updates, 2011
Novagali Pharma SA - Dormant Developmental Projects, 2010
Novagali Pharma SA, Deals Summary, 2004 to YTD 2011
Novagali Pharma SA, Deals Summary by Region, 2004 to YTD 2011
Novagali Pharma SA, Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Novagali Pharma SA – Pipeline by Therapy Area and Indication, 2011
Novagali Pharma SA – Pipeline by Stage of Development, 2011
Novagali Pharma SA – Monotherapy Products in Pipeline, 2011
Novagali Pharma SA – Pipeline By Therapeutic Class, 2011
Novagali Pharma SA - Pipeline By Target, 2011
Novagali Pharma SA – Pipeline By Route of Administration, 2011
Novagali Pharma SA – Pipeline By Molecule Type, 2011

Ask Your Question

Novagali Pharma SA – Product Pipeline Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: